Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
2020 Life Science Innovation Northwest - Speakers (Subject to Change)
Share |

KEYNOTE SPEAKER

DAY 1

Dr. Thomas Lynch

Thomas Lynch Jr, MD

President and Director, Fred Hutch

Dr. Thomas J. Lynch Jr. is a world-renowned scientist, highly respected oncologist and successful NCI-designated comprehensive cancer center leader. As the incoming President and Director of Fred Hutchinson Cancer Research Institute, Dr. Lynch brings more than three decades of experience at highly regarded U.S. cancer centers. He has expertise in solid tumor research, precision medicine and discoveries in fundamental biology. Before joining Fred Hutch, Dr. Lynch was most recently chief scientific officer at Bristol-Myers Squibb. Prior to that he held leadership roles as CEO of Massachusetts General Physicians Organization, director of Yale Cancer Center, physician-in-chief at Yale's Smilow Cancer Hospital, as well as chief of hematology-oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical School. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.

FIRESIDE CHAT

Robert Nelsen, Arch Venture Partners

Robert Nelsen, MBA

Co-founder & Managing Director, Arch Venture Partners

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including twenty-seven which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Beam Therapeutics (BEAM); Karuna Therapeutics (KRTX); Lyell Immunopharma; Array BioPharma (ARRY); Unity Biotechnology (UBX); Hua Medicine (2552:HK); Vir Biotechnology (VIR); Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL; Gossamer Bio (GOSS); Ikaria; Kythera Biopharmaceuticals (KYTH); Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics (RUBY); Syros Pharmaceuticals (SYRS); Sana Biotechnology; KSQ Therapeutics; NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Fate Therapeutics (FATE); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Editas (EDIT); 10x Genomics; Semma Therapeutics; IDUN Pharmaceuticals; Classmates.com; Sienna Biopharmaceuticals (SNNA); Fate Therapeutics (FATE); and Everyday Learning Corporation.

Mr. Nelsen is a director of Vir Bio, GRAIL, Sana Biotechnology, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.

Luke Timmerman

Journalist, Timmerman Report

Luke Timmerman is an award-winning journalist who has been covering biotechnology since 2001. Before founding Timmerman Report in 2015, Luke wrote about the industry for a regional newspaper (The Seattle Times), a global financial publication (Bloomberg News), and an online startup (Xconomy). Luke's first book,"Hood: Trailblazer of the Genomics Age" was called a"must-read" by Forbes, and named one of the"100 Best Indie Books of 2017" by Kirkus Reviews.

Luke was named one of the 100 Most Influential People in Biotechnology by Scientific American in 2015. He has won a number of journalism prizes, including the Scripps Howard National Journalism Award, the Association of Health Care Journalists Award, and the Society of American Business Editors and Writers (SABEW) award. Luke received his bachelor's degree in journalism from the University of Wisconsin-Madison in 1997. For the 2005-2006 academic year, he was awarded a Knight Science Journalism Fellow at MIT.

Outside of work, Luke enjoys running, family camping trips, and mountaineering. He reached the summit of Mt. Everest, the highest mountain in the world at 29,029 feet/8,848 meters, on May 22, 2018. Luke’s Climb to Fight Cancer campaigns have raised $1.9 million for cancer research at Fred Hutch. He lives in Seattle with his wife and daughter.

DAY 2

Kim Branson, PhD

Senior VP and Global Head of AI/ML, GlaxoSmithKline

Kim Branson has been involved in large scale machine learning and medical informatics initiatives for over 15 years, over a range of ventures from computational drug design to disease risk prediction.

Prior to joining GSK, Kim was Head of Artificial Intelligence for the Informatics department of Early Clinical Development at Genentech. He also served as Founding Chief Data Scientist at Lumiata, a predictive health analytics company. Kim received degrees from the University of Adelaide, and a PhD from the University of Melbourne. He was a Peter Doherty fellow and received postdoctoral training at Stanford University. He held leadership and consulting roles in the pharmaceutical and medical informatics industry, notably at Vertex Pharmaceuticals. Following this, Kim worked extensively in online search as a founding member of Discovery Engine (acquired by Twitter in 2009) and in Health Informatics as the Founding Chief Scientist of Gliimpse (acquired by Apple in 2017).

PANEL CHAIRS & SPEAKERS

Bonnie H. Anderson

Chairman of the Board and Chief Executive Officer, Veracyte

Bonnie H. Anderson is Chairman and Chief Executive Officer of Veracyte, a leading genomic diagnostics company that improves the lives of patients by providing answers to challenging clinical questions. The company’s first-to-market tests are developed using RNA whole-transcriptome sequencing and machine learning and are transforming care in thyroid cancer, lung cancer and idiopathic pulmonary fibrosis where they improve diagnosis and inform treatment decisions. Ms. Anderson’s career spans over 30 years in regulated diagnostics and life science markets. She cofounded Veracyte in 2008 and served as the company’s President and Chief Executive Officer until 2016, when she was also appointed Chairman of the Board. She led Veracyte’s initial public offering in 2013 and has spearheaded commercialization of Veracyte’s market-leading products.

Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the boards of the Biotechnology Innovation Organization (BIO) and Castle Biosciences and is President of the Coalition for 21st Century Medicine. She is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences.

Larry Corey, MD - Fred Hutch

Larry Corey, MD

President and Director Emeritus, Fred Hutch

Dr. Larry Corey is an internationally renowned expert in virology, immunology and vaccine development, and the former president and director of Fred Hutch. His research focuses on herpes viruses, HIV and other viral infections, particularly those associated with cancer. He is principal investigator of the HIV Vaccine Trials Network, which conducts studies of HIV vaccines in over 30 cities on five continents. Under his leadership, HVTN has become the model for global, collaborative research. In the early 1980s, working at Burroughs-Wellcome with future Nobel laureate Dr. Gertrude Elion, he developed acyclovir as the first effective therapy for genital herpes. As director of the AIDS Clinical Trials Group, he led the organization that proved combination antiretroviral treatments could control HIV. The team later demonstrated that these drugs could reduce transmission of HIV from mothers to their infants. He also showed that HIV-1 replicates in blood early in disease, emphasizing the importance of early therapy. Dr. Corey’s group studies how immune cells control HSV. Their goal is to make a vaccine that will reduce reactivation of that virus.

Congresswoman Suzan DelBene Washington State

Suzan DelBene, MBA

Congresswoman, Washington's First Congressional District

Congresswoman Suzan DelBene represents Washington's First Congressional District, which spans from northeast King County to the Canadian border, and includes parts of King, Snohomish, Skagit and Whatcom counties.

First sworn into the House of Representatives on Nov. 13, 2012, Suzan brings a unique voice to the nation's capital, with more than two decades of experience as a successful technology entrepreneur and business leader.

Suzan takes on a wide range of challenges both in Congress and in the First District and is a leader on issues of technology, health and agriculture.

Suzan currently serves on the House Ways and Means Committee, which is at the forefront of debate on taxes, healthcare and retirement security. There, Suzan is working to ensure all Americans have meaningful access to affordable, quality healthcare. She serves on the Select Revenue Measures, Trade, and Oversight Subcommittees.

Jeff Elton, PhD

Chief Executive Officer, ConcertAI

Jeff Elton, PhD, is CEO of ConcertAI, a rapidly growing Precision Oncology company with facilities in New York, Philadelphia, Los Altos, and Bangalore that recently moved its headquarters to Boston. ConcertAI is a partner with the American Society of Clinical Oncology’s CancerLinQ program, working with that group and U.S. FDA to advance the use of real world data for pre- and post-approval regulatory submissions, outcomes studies, and value-based care. Previously, he was Managing Director, Accenture Strategy & Predictive Health Intelligence, global COO of Novartis’ Institutes for BioMedical Research and a McKinsey partner in Pharmaceuticals & Medical Products. Dr. Elton co-authored, “Healthcare Disrupted: Next Generation Business Models and Strategies” in 2016, creating an industry roadmap for AI, advanced analytics, real-world data and digital medical solutions.

Simone Fishburn, PhD

Vice President and Editor in Chief, BioCentury Inc.

Simone serves as Vice President and Editor in Chief at BioCentury, bringing experience from both industry and academia in translational science, where she focused for over 15 years on the scientific, commercial and strategic considerations for advancing laboratory discoveries to products for patients.

Since joining BioCentury in 2013, Simone has written and edited on innovation from idea to patient, most recently serving as Executive Editor. Previously, she was a director of translational research at Nektar Therapeutics and a senior managing consultant at Exponent Inc., where she specialized in projects for the biopharma industry. Simone serves as an adviser on multiple university translational programs, including initiatives at the University of California and Stanford University. Simone is also active in programs to advance women's careers; she is a board member of Women In Bio and served as its President in 2013-14.

Simone is a Fulbright scholar and performed a post-doc at the University of California San Francisco. She holds a Ph.D. in Molecular Pharmacology from the Weizmann Institute of Science, and an M.A. and B.A. in Pharmacology from Cambridge University.


Wende Hutton, MBA

General Partner for West Coast, Canaan

Wende identifies, builds and invests in companies that change medicine by bringing novel drugs, technologies and devices to market. She has partnered with founders to deliver more than a dozen of those innovations to patients. She started her venture career as a General Partner at Mayfield. She previously held senior marketing roles at GenPharm and Nellcor. Wende holds an A.B. in human biology from Stanford University and an M.B.A. from Harvard Business School.

Lara Mangravite, PhD

President, Sage Bionetworks

Lara Mangravite, PhD, is President of Sage Bionetworks. This organization is focused on the development and implementation of practices for large-scale collaborative biomedical research. Our work is centered on new approaches to scientific process that use open systems to enable community-based research regarding complex biomedical problems. Previously, Dr. Mangravite served as Director of the Systems Biology research group at Sage Bionetworks where she focused on the application of collaborative approaches to advance understanding of disease biology and treatment outcomes at a systems level with the overriding goal of improving clinical care. Dr. Mangravite obtained a BS in Physics from the Pennsylvania State University and a PhD in Pharmaceutical Chemistry from the University of California, San Francisco. She completed a postdoctoral fellowship in cardiovascular pharmacogenomics at the Children's Hospital Oakland Research Institute.

Laurie McGraw

Senior Vice President, Health Solutions Group

Laurie McGraw is the Senior Vice President of Health Solutions, the unit that provides AMA's data solutions (CPT®, physician data) used across the entire US healthcare industry and increasingly, globally. For over 25 years, she has led high-growth health information companies, bringing innovative technology to healthcare.

Her first ten years were at IDX Corporation and its internet spin off ChannelHealth where she led electronic health record (EHR) product development. Prior to joining the AMA in 2016 McGraw led a clinical documentation startup after having spent 14 years at Allscripts where she held a variety of senior leadership positions—including chief client officer, president of strategic accounts and president of enterprise solutions—and was primarily responsible for running its flagship EHR businesses. McGraw&pos;s tenure at Allscripts coincided with its growth from a $30 million company with five initial clients to a $1.5 billion company serving the needs of tens of thousands of clients across the health care spectrum.

McGraw is a graduate of Brown University, where she earned a Sc.B. in cognitive science. She is also a passionate outdoor enthusiast and has served on the Yellowstone Park Foundation's Advisory Board for many years. Laurie and her husband, Kevin, have two children, Colin and Chelsea.

Trevor Moody, MScM

Partner, Medical Devices, M.H. Carnegie & Co.

Trevor has broad, global experience with over 25 years in growth-oriented medical technology markets. Trevor’s 25+ year career in medical technology has included roles in product development, marketing, management consulting and venture capital investing. Trevor has been instrumental in working with M. H. Carnegie & Co. to build their healthcare portfolio. He has been directly involved in sourcing, negotiating and managing investments in high-growth medical device companies including Cardiac Dimensions (percutaneous mitral valve repair), Serene Medical (aesthetic medical devices), Renew Medical (accidental bowel leakage), Simplify Medical (cervical spinal disc replacement) and EBR Systems (leadless pacemaker). In 2015 Trevor also served as Interim CEO of Cardiac Dimensions.

Trevor serves on the board of the Center for Infectious Disease Research, the largest independent, non-profit research institute in the US focused on vaccines, therapeutics, and diagnostics for diseases of the developing world. He was the board chair from 2012 to 2014. He is also on the board of ElectroCore, Renew Medical, Serene Medical, Simplify Medical, Cardiac Dimensions and EBR Systems.

Neil Oberoi, MBA

Senior Managing Director, Guggenheim Securities

Neil Oberoi joined Guggenheim Securities in 2015 as a Senior Managing Director and was a founding member of the firm's medical device investment banking team. Prior to joining Guggenheim Securities, Neil worked within the Healthcare Corporate Investment Banking group at Bank of America Merrill Lynch over a 12-year period, most recently as a Managing Director. He has worked on numerous merger and acquisition buy and sell-side advisory mandates and corporate financings. Mr. Oberoi received an M.B.A from Columbia Business School with honors and a B.S. in biology from the University of Richmond.

Kim Popovits

Former Chairman of the Board, Chief Executive Officer and President, Genomic Health

Committed to changing the paradigm of cancer care, Kim Popovits led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. Kim served as Genomic Health’s Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to leading Genomic Health, Kim served as Senior Vice President, Marketing and Sales at Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer.

Kim currently serves on the boards of the Coalition for 21st Century Medicine, the Personalized Medicine Coalition, MyoKardia, Inc. and Kiniksa, Inc.

Kim also serves as an Advisor to the Healthcare Businesswomen’s Association (HBA). Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 as well as one of the Most Influential Women in the Bay Area by the San Francisco Business Times. She was also named Woman of the Year in 2008 by Women Health Care Executives (WHCE).

Kim holds a Bachelor of Arts degree in Business from Michigan State University.

Chad Robins, MBA

Chief Executive Officer and Co-founder, Adaptive Biotechnologies

Chad Robins co-founded our company in September 2009 and has served as our Chief Executive Officer and a member of our board of directors since incorporation. Prior to co-founding our company, Chad held numerous executive-level positions in medical technology, investment and real estate companies. Chad holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Managerial Economics from Cornell University.

Julie Sunderland, MBA

Managing Director, Biomatics Capital

Prior to co-founding Biomatics Capital Partners in 2016, Ms. Sunderland was director of Program Related Investments for the Bill & Melinda Gates Foundation. She led the foundation’s $1.5 billion strategic investment pool, which focused on global health, global development and education. She funded 50 investments, including 30 in health care, and built a team of 10 investment professionals.

Ms. Sunderland also chaired Bill & Melinda Gates Foundation's investment committee, which reviews all program-related investments. Prior to that role, she advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs. Ms. Sunderland holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies.

Ms. Sunderland sits on the Board of Directors for several of Biomatics' portfolio companies including Aledade, BlackThorn, eGenesis and Verana.


Brad Vale, PhD

Founder and General Partner, Strategic Healthcare Investment Partners

Brad is a founding general partner of Strategic Healthcare Investment Partners.

He currently serves on a number of private company boards and one public board, Nevro, where he was an investor prior to the IPO. Brad led JJDC investments in a number of companies that were ultimately acquired by JNJ, including Biosense, Atrionix, and Indigo Medical.

Brad was Head of Johnson & Johnson Development Corporation (JJDC) from 2011 to 2015. JJDC is Johnson & Johnson's venture investing arm and has investors based in Si-Valley, Boston, Shanghai, London and Tel Aviv. He established JJDC's west coast office in 1997 and was an investor in medical devices, healthtech, and biotech for JNJ from 1992-2011.

Prior to JJDC, Brad worked in preclinical surgery and product development at Ethicon, JNJ's wound closure company, in projects to develop lasers, blood compatible polymers, wound healing stimulation, internal and external stapling and suture materials. Prior to joining JJDC he was in JNJ's Corporate Office of Science and Technology focused on next generation procedures and biomaterials for medical device applications.

Dr. Vale received a PhD in Biomedical Engineering from Iowa State University on the development of blood compatible polymers and a Doctor of Veterinary Medicine from Washington State University.

Sarah Warren, PhD

Senior Director of Translational Science, nanoString Technologies

Sarah Warren is the Senior Director of Translational Science at nanoString Technologies where she leverages multiplexed, molecular profiling technologies to address key research areas in oncology, immunology, and beyond. Her role enables her to work with academics, biopharmas, and clinicians to identify unmet needs in translational research and create novel products for transcriptional and proteomic profiling. She is also active in the immuno-oncology research community to promote the science and application of cancer immunotherapy to improve patient outcomes. Prior to joining NanoString, she was a founder and director of research at Oncofactor Corp., a Seattle biotech startup focused on developing therapeutics which targeted novel immune checkpoints. She has a PhD in immunology from the University of Washington and performed her graduate work at the Institute for Systems Biology.

David Weinreich, MD, MBA

Senior Vice President, Global Clinical Development, Regeneron Pharmaceuticals, Inc.

David Weinreich, MD, joined Regeneron as Senior Vice President, Late Stage Clinical Development and Medical Affairs in 2016. In 2017 he became the Senior Vice President, Global Clinical Development. Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Prior to Bayer, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his MD from Boston University School of Medicine, his MBA from the McDonough School of Business at Georgetown University and his BS in computer engineering from Columbia University.

Membership Management Software Powered by YourMembership  ::  Legal